Albuterol use in infants
Pro Research Analysisby 
Searched over 200M research papers
Efficacy of Albuterol in Infants with Wheezing and Bronchiolitis
Several studies have examined the use of albuterol in infants with wheezing or bronchiolitis, with mixed results. Some research shows that nebulized albuterol can improve wheeze scores, accessory muscle use, and oxygen saturation in infants presenting with wheezing or bronchiolitis in emergency settings, suggesting short-term benefits in respiratory distress reduction 15. However, other studies in hospitalized infants with moderate or severe bronchiolitis found no significant improvement in oxygen saturation, time to discharge, or length of hospital stay when using nebulized albuterol compared to placebo 34. In fact, one study noted that albuterol use in young infants with RSV bronchiolitis might increase the need for supplemental oxygen and length of stay, raising concerns about potential harm in this group .
Albuterol Use in Mechanically Ventilated and Preterm Infants
For preterm or ventilated infants, the response to albuterol is variable. In ventilated infants with severe bronchopulmonary dysplasia (sBPD), albuterol did not significantly improve expiratory flow compared to saline, though higher doses did reduce inspiratory pressures and slightly increased heart rate, indicating the need for close monitoring . In mechanically ventilated preterm infants, about two-thirds showed decreased airway resistance after albuterol, but the effect diminished with repeated doses, and changes in oxygen needs were inconsistent .
Oral Albuterol in Infants with Viral Bronchiolitis
Oral albuterol has not shown benefit in infants with mild-to-moderate acute viral bronchiolitis. A randomized controlled trial found no significant difference in illness resolution, feeding, sleeping, or respiratory symptoms between infants receiving oral albuterol and those given placebo. The study concluded that routine use of oral albuterol in this population is not recommended .
Safety of Albuterol in Infants
Albuterol, whether nebulized or continuous, appears generally safe in infants and children, with no significant evidence of cardiotoxicity or serious side effects in monitored settings. Some studies reported minor increases in heart rate, but no arrhythmias or cardiac ischemia were observed, even with continuous nebulized therapy 58. However, close monitoring is advised, especially with higher doses or in vulnerable populations such as ventilated infants .
Albuterol for Transient Tachypnea of the Newborn
Inhaled albuterol has shown promise in managing transient tachypnea of the newborn (TTN). One study found that albuterol significantly reduced respiratory distress scores and accelerated symptom resolution compared to placebo, suggesting it may be an effective and safe option for TTN management .
Variation in Clinical Practice and Guidelines
There is significant variation in albuterol use for infants with bronchiolitis across different hospitals and regions, partly due to evolving guidelines and differing interpretations of the evidence. While some guidelines now recommend against routine albuterol use in bronchiolitis, some clinicians still consider a therapeutic trial reasonable, especially in cases with prominent wheezing .
Conclusion
Albuterol may provide short-term relief of respiratory distress in some infants with wheezing or bronchiolitis, particularly in emergency settings. However, evidence does not support its routine use in hospitalized infants with bronchiolitis or in mild-to-moderate viral bronchiolitis, especially via the oral route. Inhaled albuterol may be beneficial for transient tachypnea of the newborn. Overall, albuterol is generally safe in infants, but careful monitoring is recommended, especially in preterm or ventilated infants. Clinical decisions should be individualized, considering the specific diagnosis, severity, and evolving guidelines.
Sources and full results
Most relevant research papers on this topic
The Use of Albuterol in Hospitalized Infants With Bronchiolitis
Nebulized albuterol therapy does not appear to enhance recovery or attenuate severity of illness in infants hospitalized with acute, moderate bronchiolitis, as evidenced by improvement in oxygen saturation, time to meet standardized discharge criteria, or length of hospital stay.
The Use of Albuterol in Young Infants Hospitalized with Acute RSV Bronchiolitis
Albuterol use in young infants with RSV bronchiolitis does not appear to be useful and may increase supplemental oxygen need, potentially harming their recovery.
Tolerability and Efficacy of Two Doses of Aerosolized Albuterol in Ventilated Infants with BPD
Aerosolized albuterol at 1.25mg and 2.5mg doses did not affect expiratory flow at 75% of exhalation in infants with severe bronchopulmonary dysplasia receiving invasive ventilation, but 2.5mg dose showed greater inspiratory pressure improvement.
DOI